Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-06
2007-11-06
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S079000
Reexamination Certificate
active
11179610
ABSTRACT:
A pharmaceutical composition comprising a compound of Formula Iwherein R1is selected from, inter alia, alkyl, aryl-loweralkyl, heterocycle-loweralkyl, loweralkyl-carbonate; optionally substituted amino; benzimidaz-2-yl; optionally substituted phenyl; loweralkyl-(R5)(R6) wherein one of R5and R6is selected from H and and the other is selected from carboxy, carboxy-loweralkyl and lower alkoxycarbonyl; NHCH2CH2OX wherein X represents an in vivo hydrolyzable ester; and R2and R3are independently selected from H, NO2, halo, di(loweralkyl)amino, cyano, C(O)OH, phenyl-S-, loweralkyl, and Z(O)OR7wherein Z is selected from C and S and R7is selected from H, lower alkylamino and arylamino; or pharmaceutically acceptable salts or certain in vivo hydrolyzable esters or amides thereof, in an amount effective to inhibit neurotrophin-mediated activity, and a suitable carrier, is described.The compositions are useful to inhibit undesirable neurotrophin-mediated activity such as the neurite outgrowth that occurs in some neurodegenerative disease states.
REFERENCES:
patent: 3821383 (1974-06-01), Sestanj
patent: 4006238 (1977-02-01), Wade
patent: 4204063 (1980-05-01), Brana
patent: 4254109 (1981-03-01), Sestanj
patent: 4874863 (1989-10-01), Brana
patent: 5076831 (1991-12-01), Saupe et al.
patent: 5183821 (1993-02-01), Brana
patent: 5342942 (1994-08-01), Jaen et al.
patent: 5420137 (1995-05-01), Brana
patent: 5552544 (1996-09-01), Brana
patent: 5554622 (1996-09-01), Brana
patent: 5616589 (1997-04-01), Keilhauer et al.
patent: 6029114 (2000-02-01), Shamovsky et al.
patent: 6291247 (2001-09-01), Riopelle et al.
patent: 6300331 (2001-10-01), Noguchi et al.
patent: 6468990 (2002-10-01), Ross et al.
patent: 6492380 (2002-12-01), Ross et al.
patent: 7148352 (2006-12-01), Ross et al.
patent: 43963/09 (2000-01-01), None
patent: 2323555 (1974-08-01), None
patent: 3707652 (1988-09-01), None
patent: 0206322 (1986-12-01), None
patent: 0 268 093 (1988-05-01), None
patent: 2521139 (1983-08-01), None
patent: WO98 17278 (1998-04-01), None
patent: WO98 34632 (1998-08-01), None
patent: WO98 52919 (1998-11-01), None
patent: WO 00 00472 (2000-01-01), None
Neuron Abstract Vassilis et al 1993 Evidence that brain -derived neurotrophic factor is a trophic factor for motor neurons in vivo.
Katsuhiro et al. 1997. Antinociceptive Effects of Neurotrophin in a rat model of painful peripheral mononeuropathy.
Brana, M.F., et al. “Enediynes as Antitumor Compounds: Synthesis of Tetrahydropyridine Derivatives,” J. Org. Chem., 61: 1369-1374 (1996).
Brana, M.F., et al. “Synthesis and cytostatic activity of benz(de)isoquinolin-1,3-diones. Structure-activity relationships,” Eur. J. Med. Chem-Chimica Therapeutica, 16(3): 207-212 (1981 (May-June).
Arient, J. and Marhan, J., “Imidazolfarbstoffe VI. Synthese und Eigenschaften des 1,2-Naphtholylenbenzimidazols,” Collection Czechoslov. Chem. Commun. 26: 2774-2780 (1961).
Jaen, J.C. et al., “Kynurenic Acid Derivatives Inhibit the Binding of Nerve Growth Factor (NGF) to the Low-Affinity p75 NGF Receptor,” J. Med. Chem. 38: 4439-4445 (1995).
Spiegel, K. et al., “PD 90780, A Non Peptide Inhibitor of Nerve Growth Factor's Binding to the P75 NGF Receptor,” Biochemical and Biophysical Research Communications 217(2): 488-494 (Dec. 14, 1995).
Owolabi, J.B. et al., “Characterization of Antiallodynic Actions of ALE-0540, a Novel Nerve Growth Factor Receptor Antagonist, in the Rat,” J. of Pharmacology and Experimental Therapeutics 289(3): 1271-1276 (1999).
Bailleux, V. et al., “Synthesis and Anticonvulsant Activity of Some N-Phenylphthalimides,” Chem. Pharm. Bull. 42(9): 1817-1821 (1994).
Bailleux, V. et al., “Comparative Anticonvulsant Activity and Neurotoxicity of 4-Amino-N- (2,6-Dimethylphenyl) Phthalimide and Prototype Antiepileptic Drugs in Mice and Rats,” Epilepsia 36(6): 559-565 (1995).
Bailleux, V. et al., “Anticonvulsant activity of some 4-amino-N-Phenylphthalimides and N- (3-amino-2-methylphenyl)phthalimides),” Biomed & Pharmacother 48: 95-101 (1994).
Shibata, Y. et al., “Phenylphthalimides with Tumor Necrosis Factor Alpha Production-Enhancing Activity,” Chem. Pharm. Bull. 44(1): 156-162 (1996).
Chapman, J.M. et al., “Hypolipidemic Activity of Phthalimide Derivatives. 2. N-Phenylphthalimide and Derivatives,” J. Med. Chem. 26: 237-243 (1983).
Chapman, J.M. et al., “Hypolipidemic Activity of Phthalimide Derivatives. 3. A Comparison of Phthalimide and 1,2-Benzisothiazolin-3-one 1,1-Dioxide Derivatives to Phthalimidine and 1,2-Benzisothiazoline 1,1-Dioxide Congeners.” J. Med. Chem. 26: 243-246 (1983).
Chapman, J.M. et al., “Hypolipidemic Activity of Phthalimide Derivatives IV: Further Chemical Modification and Investigation of the Hypolipidemic Activity of N-Substituted Imides,” J. Pharmaceutical Sciences 72(11): 1344-1347 (1983).
Chapman, J.M. et al., “Hypolipidemic Activity of Phthalimide Derivatives V: Reduced and Hydrolytic Products of Simple Cyclic Imides,” J. Pharmaceutical Sciences 73(10): 1482-1484 (1984).
Tyman, J.H.P., “Fluorescent naphthalimide dyes,” Chemical Abstract 108: 7506 (1997).
Maybridge—Online Catalogue Search Page (Jan. 8, 2001).
Ryan Scientific Inc. Online Search Page (Jan. 8, 2001).
Costi, M.P. et al., Eur J. Med. Chem. (1996) 31, 1011-1016.
Bundgaard H. (1985), Design of Prodrugs, Elsevier, Amsterdam-New York-Oxford, pp. 1-3, 27-28.
Information data sheet for PHG 01006, Ryan Scientific, Inc.
Kubinyi H. Die Pharmazie, (Oct. 1995) 50 (10) 647-62.
U.S. Appl. No. 11/525,841.
U.S. Appl. No. 11/627,129.
Chemical Abstracts 88:154305.
Laszlo Biczok et al., Phys. Chem. Chem. Phys. I: pp. 4759-4766 (Aug. 23, 1999).
Donker et al., “Synthesis and biological activities of aldose reducstase inhibitors bearing acyl benzensulfonamides as carboxylic acid surrogates”, Eur. J. Med. Chem. 33: 15-22 (1998).
Donker et al., “Synthesis and biological activity of aldose reductase inhibitors with Michael acceptor substituents”, Eur. J. Med. Chem. 34: 235-243 (1999).
Dubey et al., “A novel bifunctional fluorescent tag for use in molecular biology”, Indian J. Chem. 34B: 876-878 (Oct. 1995).
Hodgkiss et al., “Fluorescent markers for hypoxic cells: a study of novel heterocyclic compounds that undergo bioreductive binding”, Biochem. Pharmocol. 41: 533-541 (1991).
Hodgkiss et al., :Toxicity of 3-nitronaphthalimides to V79 379A Chinese hampster cells, Biochem. Pharmacol. 36: 1483-1487 (1987).
Szadowski et al., “Przemsyl Chemizny” 57(2): 70-74 (1978).
Nishizaki et al., “Infrared spectra of N-substittued naphthalimides”, Nippon Kagaku Zasshi 86(7): 696-9 (1965) (Japan).
Lesauteur et al., “The Journal of Biochemistry”, 1995, 270(12): 6564-69.
Gray et al., “Analytical Biochemistry”, 1994, 216(1): 89-96.
Chen Xiannong
Tehim Ashok
Desai Rita
Nassif Omar A.
Painceptor Pharma Corporation
LandOfFree
Neurotrophin antagonist compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neurotrophin antagonist compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurotrophin antagonist compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3820280